Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

Business Wire December 1, 2023

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

GlobeNewswire November 28, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire November 21, 2023

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

PR Newswire November 16, 2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

Business Wire November 2, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire November 2, 2023

Pfizer Reports Third-Quarter 2023 Results

Business Wire October 31, 2023

FDA Approves PENBRAYA(TM), the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

Business Wire October 20, 2023

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

PR Newswire October 15, 2023

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

PR Newswire October 15, 2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

GlobeNewswire October 15, 2023

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

Business Wire October 13, 2023

U.S. FDA Approves Pfizer's VELSIPITY(TM) for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Business Wire October 13, 2023

U.S. FDA Approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Business Wire October 12, 2023

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

Business Wire October 5, 2023

Pfizer Declares Fourth-Quarter 2023 Dividend

Business Wire October 4, 2023

Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer

PR Newswire September 27, 2023

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO(TM) for RSV

Business Wire September 22, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire September 19, 2023

European Commission Approves Pfizer's LITFULO(TM) for Adolescents and Adults With Severe Alopecia Areata

Business Wire September 19, 2023